Abnormal high activation of survivin is involved in carcinogenesis of various types of cancer. Survivin has been shown to promote cell proliferation in human hepatocellular carcinoma (HCC). Survivin-targeting approaches have become a promising strategy for treating HCC. Here, we used a reporter system to screen effective survivin siRNA sequences. The effect of vector-based survivin short hairpin RNA (shRNA) on the malignant phenotype of HCC cells in vitro and in vivo was determined, and an adenovirusmediated shRNA expression vector was developed to decrease survivin expression of the established HCC tumor in nude mice. In vitro study showed that stable survivin knockdown inhibited cancer cell proliferation, enhanced apoptotic susceptibility, arrested cell cycle in the G1 phase and resulted in apparent mitotic catastrophe. Moreover, cells stably expressing survivin shRNA showed decreased tumorigenicity in nude mice. An additional in vivo study showed that intratumoral injection of adenovirus-delivered survivin shRNA suppressed tumor growth by spontaneous apoptosis of cancer cells and significantly prolonged animal survival. In conclusion, we proved the therapeutic potential of survivin shRNA for the treatment of HCC. And our results indicated that adenovirus-delivered shRNA may serve as a novel therapeutic for HCC.
Introduction
Survivin is a member of the inhibitor of apoptosis (IAP) family of antiapoptotic proteins and is conserved throughout evolution, with homologs found in both vertebrate and invertebrate animals. Human survivin has a dual role in both antiapoptosis and cell-division regulation. [1] [2] [3] [4] Clinical studies have shown that survivin overexpression is strongly correlated with recurrence and a poor survival rate in many types of neoplasms. 1 Most importantly, survivin is overexpressed in malignant tumor tissues, whereas its expression is low or even undetectable in terminally differentiated adult tissues. Therefore, survivin is considered to be an attractive target for cancer gene therapy. 1 Attenuation of survivin expression or function by using antisense oligonucleotides, ribozymes, small interfering RNAs (siRNAs), or dominant-negative mutants has been shown to induce apoptosis or mitotic catastrophe in multi types of cancer. [5] [6] [7] [8] [9] [10] The use of RNA interference (RNAi) has grown at a remarkable rate since the first discovery of RNAi in Caenorhabditis elegans. 11 Subsequently, RNAi was shown to occur in mammalian cells in response to doublestranded siRNAs of B21 nt in length that serve as the effector molecules of sequence-specific gene silencing. 12 Owing to the specificity and efficiency in gene silencing, vector-based short hairpin RNAs (shRNAs) and chemically synthesized siRNA oligonucleotides targeting oncogenes that are overexpressed or highly active in cancer cells have been increasingly investigated for the development of cancer therapeutics. 13 Hepatocellular carcinoma (HCC) is an aggressive cancer with a poor prognosis. Despite aggressive surgical resection and chemotherapy, nearly 50% patients develop recurrent disease. Although many treatment strategies have been developed, the prognosis remains unsatisfactory. 14 Understanding the molecular mechanisms involved in the carcinogenesis of HCC is very important for developing more effective treatment modalities. Supportive evidence has suggested that survivin promotes cell proliferation in human HCC both in vitro and in vivo. 15 It has been demonstrated that survivin overexpression in HCC cells obliterates the G1 checkpoint by releasing p21 WAF1/Cip1 from the p21/cyclin-dependent kinase 4 complex and enforces procaspase 3/p21 complex formation to suppress cell death signaling. These observations indicate that survivin may have an important role in the progression of HCCs. 16 Although it has been demonstrated that interference with survivin expression or function could inhibit the neoplastic growth of a wide variety of cancers, to date, there are still few reports to experimentally support this theory in HCC. 17 We reasonably postulate that survivin may be a promising and powerful target for the treatment of HCC. Here, we discuss our study of the applicability of the vector-based and adenovirus-delivered shRNA as therapy against survivin overexpression in HCC by ex vivo and in vivo experiments.
Materials and methods

Cell culture
HepG2, BEL7404, HHCC, Huh7, SMMC-7721 and 293 T cells were all grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Primary human hepatocytes (PHHs) were isolated from the fresh surgical specimens of patients undergoing partial hepatectomy for hemangioma. Informed consent was obtained from each patient and the procedure was approved by the local medical committee. Healthy liver tissue was used to isolate normal PHHs by a 2-step collagenase perfusion and PHHs were cultured according to the established methods. All cells were maintained in a humidified 37 1C incubator with 5% CO 2 .
Generation of plasmids and siRNA design Constructs expressing survivin and luciferase fusion gene were generated by amplifying the survivin gene from cDNA of HepG2 cells and the luciferase gene from pGL3-basic vector (Promega, Madison, WI 
Construction and production of recombinant adenoviruses
The expression cassettes of all shRNAs were subcloned into the pShuttle vector. Preparation and construction of Ad-shGFP and Ad-shSur vector, and adenovirus titration were carried out as previously described.
18
Dual Luciferase assay Cells were cotransfected with the plasmids expressing firefly luciferase, pTK-RL (Promega), and synthetic siRNAs or vector-based shRNAs. The relative amounts of renilla and firefly luciferase were analyzed by a dual luciferase assay (Promega) using an EG&G Berthold luminometer.
Cell Viability assay
Cells were subjected to [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (Sigma, St Louis, MO) to detect cellular growth. For colony formation assay, transfected cells were cultured in G418 selective medium for 3 weeks. The G418 concentration is 0.6 mg ml À1 for HepG2 cells, 0.8 mg ml À1 for Huh7 cells and 1 mg ml À1 for HHCC, BEL7404 and SMMC-7721 cells. Drug-resistant colonies were fixed with cold methanol, stained with crystal violet and then scored numbers of colony. For soft agar growth assay, cells were plated in the medium containing 0.3% agar. The dishes were examined microscopically for colony formation after a 2-week incubation period.
Antibodies for western blot analysis
Survivin and XIAP polyclonal antibodies were from Cell Signaling Technology (Beverly, MA). GFP monoclonal antibody was from Clontech (Mountain View, CA). poly(ADP-ribose) polymerase (PARP) and b-actin polyantibodies were from Santa Cruz (Santa Cruz Biotechnology, CA). Active caspse-3 polyclonal antibody was from BD pharmingen (San Jose, CA).
Flow cytometry
Cells were collected and fixed with ice-cold 70% ethanol in PBS. After resuspension, cells were incubated with 100 ml of RNase I (1 mg ml
À1
) and 100 ml of PI (400 mg ml À1 ) at 37 1C and analyzed by flow cytometry (Coulter, Luton, United Kingdom). The cell cycle phase distribution was calculated from the resultant DNA histogram using Multicycle AV software (Phoenix Flow Systems, San Diego, CA).
Immunofluorescent and Immunohistochemical staining
Cells on coverslips were fixed in 4% paraformaldehyde, permeated with 0.25% Triton X-100 and blocked in 5% BSA. a-tubulin were detected with mouse anti-human a-tubulin monoclonal antibody (Santa Cruz), biotinlabeled anti-mouse secondary antibody (Santa Cruz) and Cy3-conjugated avidin-biotin complex (Sigma) as the tertiary reagent. For immunohistochemistry, the formalin-fixed tumor tissues were embedded in paraffin. Serial 5 mm sections were obtained with a Leica microtome. Immunohistochemical staining for PCNA (DAKO, Hamburg, Germany) was performed using the Elite ABC kit (Vector Laboratories, Burlingame, CA).
In Situ detection of apoptotic cells by TUNEL assay Tumor tissues from xenografts were excised and formalinfixed immediately after resection. TUNEL staining was carried out using the DNA Fragmentation Detection kit (Merk Corp, Darmstadt, Germany) according to the manufacturer's instructions. Nuclei with clear brown staining were regarded as positive. 6 in PBS/100 ml) were injected subcutaneously into the flanks of nude mice. Two weeks after tumor cells inoculation, mice were divided randomly into three groups (five mice/group) and were treated every 3 days for 10 days by way of multiplecenter intratumoral injection of 100 ml of Ad-shGFP or Ad-shSur at 1 Â 10 9 PFU per animal or PBS as a control. The tumors were monitored with a caliper every week for a period of time beyond 8 weeks. The tumor volume was calculated as described above. All the animal experiments have been approved by the Ethics Committee of the Fourth Military Medical University. 
Tumorigenicity assay
Statistical analysis
Statistical analysis was performed using SPSS 10.1.4 software (SPSS Inc., Chicago, IL). Results are expressed as the mean value ±s.d. The data from different treated groups were compared by using the unpaired, 2-tailed Student's t-test. A P-value of less than 0.05 was considered statistically significant.
Results
Screening of survivin siRNA by a quantitative reporter system To rapidly screen and identify the most effective survivin siRNA sequences, we established a reliable and quantitative enzymatic reporter system. We designed constructions in which the survivin gene was fused at either the N-or C-terminal of the firefly luciferase gene; the luciferase activity was considered to represent the level of survivin expression ( Figure 1a ). SiRNA sequences against survivin were selected according to the principle recommended by Tuschl ( Figure 1b ). 18 The data of luciferase assay showed that with respect to the control, two siRNAs significantly decreased the enzymatic activity of both N-and C-terminal survivin and luciferase-fused protein ( Figure 1c ). We used semi-quantitative RT-PCR to confirm the silencing effect of these two siRNAs in HepG2 and HHCC cells. The data was consistent with the data obtained in the luciferase assay ( Figure 1d ). The results indicated that only two selected survivin siRNAs can effectively silence survivin mRNA, hence, these two siRNAs were used for further studies.
Vector-based shRNAs decreased endogenous survivin expression in HHCC and HepG2 cells Although we used a quantitative enzymatic reporter system to identify the silencing effect of survivin siRNAs, it remained to confirm whether this effect could occur in natural conditions rather than in an artificial system through the use of vector-based shRNA. Hence, we examined the impact of vector-based survivin shRNAs on endogenous survivin expression in HCC cells. . Our data demonstrated that vectorbased survivin shRNA potentially suppressed the growth of a wide spectrum of HCC cell lines. To further determine the impact of stable survivin shRNA on cell growth, we established clones of HHCC cells expressing vector-based survivin shRNA. MTT assay was performed to detect the growth rate of HHCC stable colonies. The data showed that stable suppression of survivin expression resulted in a substantial decrease in cell growth with respect to the control (Figure 3c) . To examine the impact of survivin shRNA on the transformation phenotype of HHCC cells in vitro, we performed soft agar assay to detect the anchorage-independent colony formation of HHCC cells. When grown in soft agar, the number of HHCC-shSur colonies apparently reduced, and the average size of these colonies was smaller than that of the control (Figure 3d and e). The result demonstrated that RNAi-targeting survivin can inhibit cell proliferation and colony formation in monolayer cultures and even reverse malignant phenotype of HHCC cells in vitro.
Downregulation of survivin expression arrested the cell cycle in the G1 period and resulted in mitotic catastrophe in HCC cells Interestingly, morphological analysis showed that some of the HHCC-siSur cells became relatively large with multiple nuclei and abrogated polarity, indicating specific features of mitotic catastrophe (Figure 4a ). To further verify the identity of abnormal cells, we performed a-tubulin and DAPI staining to show the change in the morphology of the cells. HHCC-shSur revealed a statistically significant increase in abnormality that included multinucleated, multilobulated and abnormally large nuclei as compared with the control (Figure 4b ). We found that approximately 18% HHCC-shSur cells showed multinucleation whereas control cells showed only background multinucleation (Figure 4c ). Flow cytometry was performed to detect the distribution of the cell cycle. The data showed that HHCC-shSur cells were apparently blocked in the G1 phase, and the percentages of cells in the S and G2/M phases were correspondingly reduced ( Figure 4d ). Our findings indicated that stable survivin siRNA caused cell cycle arrest in the G1 period in HHCC cells, eventually resulting in mitotic catastrophe.
Loss of survivin expression sensitized HHCC cells to apoptotic stimulator and chemotherapeutic agentinduced apoptosis.
To investigate the impact of survivin siRNA on survival of HCC cells, we cultured HHCC-shSur cells in a serumdepleted medium for 24 h. Although the stable expression of survivin siRNA did not affect the viability of HHCCsiSur cells in the normal medium, these cells underwent apoptosis in the serum-depleted medium (Figure 5a ). FCM assay showed that HHCC-siSur cells were more sensitive than the control cells to apoptosis by serum withdrawal. An apparent subG1 peak was detected in HHCC-shSur cells 24 h after serum depletion. However, it did not affect the control cells (Figure 5a ). When the stimulation time was prolonged to 48 h, the percentage of subG1 increased in HHCC-shSur cells; however, there was no apparent sign of apoptosis in control cells although the cell cycle was arrested at the G1 phase. These results indicated that survivin-inhibited HCC cells were likely to undergo apoptosis with insufficient growth factors or nutrients. Next, we detect the response of HCC to chemotherapeutic drugs when endogenous survivin expression was downregulated. We observed the cleavage of PARP, a caspase-3-specific substrate, by western blot. In HHCC-shSur cells, the cleavage product was detected 5 h after etoposide or cisplatin treatment. PARP cleavage was rarely detected at the indicated time point in the control cells (Figure 5b and c). The result suggested that survivin siRNA sensitized HCC cells to drug-induced apoptosis and the combination of survivin siRNA and chemotherapeutic drugs may serve as a more effective treatment strategy for HCC.
Downregulation of survivin expression by stable shRNA suppressed tumorigenicity of HCC cells in nude mice
To determine the tumor suppression effect of survivin siRNA in vivo, we studied the tumorigenicity of HHCC transfectants in nude mice. Mice injected with HHCCshSur cells required longer time to develop tumors than mice injected with control cells (Figure 6a ). The average time of early tumor formation in HHCC-shSur-injected mice was more than 13.4±2.3 days, whereas the average time of early tumor formation in HHCC-shGFP-or parental cell-injected mice was 6.8 ± 1.64 and 6.4 ± 1.51 days, respectively. Compared with the control group, the stable survivin shRNA in HHCC cells significantly inhibited the tumor growth and prolonged the survival rate of tumor-bearing mice (Figure 6b and c) , whereas the survival rates of tumor-bearing mice between HHCCshGFP and HHCC groups were not statistically significant. Immunohistochemistry and western blot analysis showed that survivin expression was almost completely depleted in the tumor tissue dissected from survivin shRNA stable clone cell-injected mice and this finding was consistent with the result of our in vitro experiment (data unpublished). We next examined whether the decreased tumor growth rate was associated with increased apoptosis and/or decreased proliferation in vivo. No apparent difference was observed in the population of TUNEL-positive cells in the tumor tissue derived from mice injected with HHCC-shSur or control cells (data unpublished), while the proportion of PCNApositive cells in tumors derived from mice injected with HHCC-shSur cells was significantly lower than that in tumors derived from mice injected with control cells (Figure 6d ). The result suggested that inhibition of survivin expression was attributable to decreased cell proliferation in vivo. The observations showed that survivin siRNA exerted a negative effect on the regulation of tumorigenesis of HCC in vivo, thereby confirming the role of survivin shRNA in tumor suppression. Survivin siRNA in hepatocellular carcinoma R Zhang et al Recombinant adenovirus-mediated survivin shRNA inhibited tumor formation in nude mice It is important to note that the results of in vitro and in vivo experiments on stable RNAi suggest that survivin could be a promising target in cancer gene therapy; however, these results are inadequate to demonstrate that survivin siRNA can be used for clinical treatment. An in vivo delivery system should be developed to determine the effect of survivin siRNA in cancer therapy. Liposome-mediated plasmid-derived shRNA has been regarded as a feasible strategy in the treatment of solid tumors; however, their delivery efficacy needs to be further improved. Here, we compared the delivery efficacy of adenovirus and liposome. Adenovirusmediated GFP was used as a monitor and 2 days after intratumoral injection, adenovirus-mediated GFP expression was more extensive and intensive than the plasmidderived GFP expression was (Figure 7a-d) . This result showed that compared with encapsulated liposome, single intratumoral administration of adenovirus could maintain the expression of target genes for a long time in tumor tissues. Based on this conclusion, we developed an adenovirus delivery system to transfer shRNA into the tumor tissue (Figure 7e ). Real-time PCR and western blot were used to confirm the gene-silencing effect of adenovirus-mediated survivin shRNA in HepG2 and HHCC cells (Figure 7f and g ). To detect the activation of adenovirus-mediated survivin shRNA in vitro, we transduced HepG2 and HHCC cells with Ad-shSur or Ad-shGFP, respectively. The result of western blot showed the obvious active caspase-3 and the cleavage of PARP in Ad-shSur-treated cells (Figure 7h ). And the data of crystal violet staining also confirm the killing effect of adenovirus-mediated survivin shRNA in vitro (Figure 7i ). We next investigated whether survivin depletion reduced tumorigenicity in vivo. HHCC and HepG2 cells transduced with Ad-shSur or Ad-shGFP and intact cells were subcutaneously inoculated into nude mice, and tumor growth was monitored for 9 weeks. Intact cells and Ad-GFP-transduced cancer cells formed large tumors of more than 1000 mm 3 within 9 weeks; however, the in vivo growth of Ad-shSur-transduced cancer cells was markedly suppressed (Figure 7j ), suggesting that depletion of survivin by adenovirus-mediated shRNA results in significant inhibition of tumorigenicity in vivo. ) or cisplatin (10 mg ml
À1
) for 5 h. PARP cleavage was detected by western blot. Caspase-3 activation was indicated by the appearance of 85-kDa PARP cleavage product.
Survivin siRNA in hepatocellular carcinoma R Zhang et al PFU Ad-shSur, Ad-shGFP, or PBS every 3 days for 10 times after a 2-week inoculation of cancer cells. Rapid uptake of viral particles was apparent by 24 h after each injection; this was confirmed by injection of Ad-GFP as a reporter monitor (Figure 7b ). Tumor tissues treated with Ad-shSur grew more slowly than those treated with AdshGFP or PBS alone (Figure 8a ). Furthermore, AdshSur-treated mice showed significantly longer survival than those in the control groups ( Figure 8b ). Next, we examined whether the decreased growth rate of Ad-shSurtreated tumors was associated with spontaneous apoptosis or inhibition of proliferation in xenografts. Tumor specimens from Ad-shSur-treated mice clearly showed TUNEL-positive cells, whereas tumor specimens from PBS-or Ad-siGFP-treated mice contained low numbers of apoptotic cells (Figure 8c ). Immunostaining showed no apparent difference in PCNA-positive cells in all three groups (data unpublished). The result showed that the major factor of tumor regression in mice treated with AdshSur is the accelerated apoptosis but not the inhibited proliferation of cancer cells. Finally, we evaluated the safety of Ad-shSur in vivo by detecting the pathological changes in important metabolic organs 1 month after treatment with Ad-shSur. The liver and kidney tissues did not show apparent pathological changes with respect to the control (Figure 8d ). The result indicated that Ad-shSur treatment was safe by limited local administration. Taken together, the data suggested that survivin shRNA delivery by adenovirus can exert a strong antitumor effect in vivo on HCC and that Ad-shSur inhibited tumor growth by inducing spontaneous apoptosis of cells in tumor tissues.
Discussion
To overcome the limitations of current therapeutic modalities for liver cancer, various strategies, including Survivin siRNA in hepatocellular carcinoma R Zhang et al siRNA, have been investigated. In recent years, several oncogenes as cyclin E, p28GANK, PTTG1, etc., have been confirmed as promising targets in HCC gene therapy. SiRNA targeting these genes induced apoptosis, blocked proliferation, and even suppressed formation and growth of tumor. [19] [20] [21] [22] These results suggest that the RNAi technology would be an effective strategy for treating HCC. Clinical studies have shown that survivin overexpression was found in 70% of HCC and correlated with poor prognosis. The evidence on the molecular mechanism also showed that survivin prompted proliferation of HCC cells. 15 On the one hand, survivin has an important role in the regulation of cell division, however, on the other hand survivin, as a member of the inhibitory apoptosis family, exerts the capability of antiapoptosis and the reduced sensitization of cancer cells to chemotherapy and radiotherapy. 23 Compared with non-HCC cells, HCC cells are more sensitive to the loss of survivin function because of the higher expression of survivin. 24 All these results motivated us to determine whether survivin can be a promising target for HCC gene therapy.
Previous studies have reported that several dominantnegative mutants of survivin are reliable to induce apoptosis or mitotic catastrophe in cells. 7, 8, 25, 24 We postulated that distinct functional properties of survivin have different roles in antiapoptosis and cell mitosis. The strategy of dominant-negative mutants can only abrogate one function of survivin at one time, whereas siRNA can interrupt all the functions of survivin simultaneously and this may reinforce the inhibitory effect on the functions of survivin. 26 To date, several survivin isoforms have been reported, but the detailed biological function and mechanism are still not elucidated clearly. Given the fact that survivin is overexpressed in HCC tissue, we concluded that all survivin isoforms existing in HCC are promising targets for the treatment. And the most efficient siRNA that we selected targeted in all survivin isoforms. Compared with the antisense oligonucleotide strategy, siRNA-a double-stranded RNA-is more resistant to nuclease degradation, provides longer therapeutic effects than the antisense oligonucleotide approach and appears to be quantitatively more efficient and durable in cell culture. 27 Hence, in this study, we used the siRNA technology instead of dominant-negative mutants or antisense oligonucleotides to disrupt the function of survivin in HCC.
Selection of the most effective siRNA sequence ensures specific gene silencing. Although general guidelines for selecting siRNA to specific genes are available, 18 they cannot ensure the validation of each selected siRNA. The lack of a reliable target site selection method has imposed serious limitations on the efficiency of RNAi as a general therapeutic tool in clinical diseases. To rapidly and easily determine the effective siRNA sequence targeting survivin, we designed a quantitative siRNA screening system to determine the most effective siRNA sequences targeting survivin. The most beneficial aspect of this system is that it can rapidly and easily perform screening of a number of siRNAs, and this ability to quickly identify effective siRNAs for target genes is likely to have a significant implication in RNAi-based therapeutics. 28 Recently, it has been reported that in vivo treatment of established glioma tumors with adenovirus-containing double U6 promoters expressing survivin siRNA resulted in a significant decrease in tumor growth; however, the molecular mechanism responsible for the observed decrease in tumor growth has not been elucidated. 6 In our study, survivin knockdown by stable shRNA inhibited tumorigenicity of the HCC cells in nude mice. To analyze the mechanism of decreased tumorigenicity by stable survivin shRNA, we performed a histological experiment and found that delayed tumor growth strongly correlated with the decreased proliferation index calculated using the PCNA-labeling nuclei ratio but did not significantly correlate with the apoptosis index calculated by the TUNEL staining. However, it has been reported that survivin expression correlated with reduced tumor cell apoptosis in colorectal cancer and gastric cancer. One of the plausible explanations is that antiapoptotic mechanisms such as reduced expression of Fas and expression of antiapoptotic proteins, for example, bcl-2 or XIAP, in addition to survivin or receptormediated survival signals are involved in the progression of antiapoptosis of HCC cells. [29] [30] [31] [32] The findings of both our in vitro and in vivo studies were in good agreement; this confirmed that stable knockdown of survivin abrogated its function in cell cycle regulation, and although it cannot induce spontaneous apoptosis directly and immediately, it sensitizes HCC cells to apoptotic stimuli. Most importantly, our result was consistent with the results of a previous clinical study that survivin expression in HCC tissues strongly correlated with the proliferation index, but did not significantly correlate with the apoptosis index. 15 A recent study has shown that adenovirus could be a promising delivery system to express anti-survivin hammerhead ribozymes in vivo. 33 In our in vivo study, adenovirus-mediated survivin shRNA was intratumorally injected in nude mice. This manipulation induced obvious apoptosis in tumor tissues. The finding that the inhibitory effect of survivin shRNA on the tumor growth results from mitotic dysfunction appears to be in contrast to our inference; however, it is reasonable that cancer cells cannot adapt to a sudden downregulation of the expression of antiapoptotic molecules; in addition, other studies have validated that transient transfection of synthetic survivin siRNA directly induced cancer cell apoptosis. 4 Our in vitro study revealed spontaneous apoptotic trends in a subpopulation of cancer cells after knockdown of survivin and showed that Ad-shSur-infected HHCC cells underwent mitosis but generally failed to complete cytokinesis. In summary, interference of survivin function by using siRNA causes both spontaneous apoptosis and mitotic catastrophe of cancer cells in vitro and in vivo.
Several independent studies showed the systematic delivery strategy to introduce survivin siRNA oligonucleotides into the body, 34 ,35 whereas we performed tumorlocal region administration to inject survivin shRNA into the tumor tissue. We think that the local injection method is reasonable in the clinical application. 36, 37 To facilitate the application of siRNA in cancer gene therapy, it is necessary to develop improved approaches for efficient introduction of siRNA into target cells. 38, 39 Viral vectors are efficient transgene-carrying systems, and previous studies have shown the antitumor ability of viral vectors in vitro and in vivo by using replication-deficient adenovirus. 39, 41 Recombinant adenovirus is valuable particularly for transgene expression in hard-to-transfect cells and has been used widely in clinical and experimental conditions. Adenovirus is an efficient tool with a strong hepatotropic nature required for HCC treatment. 41, 42 In our study, a commercial adenovirus vector, namely, the Adeasy-1 system, was employed. 18 The shRNA expression cassette was introduced into the shuttle vector. High titers of recombinant adenovirus particles were obtained easily; in recombinant adenoviruses, shRNAs were delivered by the RNA PolIII H1 promoter. Adenovirusmediated survivin shRNA effectively suppressed tumor growth in vivo and significantly prolonged the survival of tumor-bearing mice. With respect to the tumor growth curve and survival rate, the effect of adenovirus treatment was not as good as that detected in the stable shRNA experiment, as shown in Figures 6b and c, and 8a and b. This may be because stable transfectants were derived from single cell clones. Theoretically, all the HHCC-siSur cells show low levels of survivin expression; thus, tumor formation and tumor growth can be inhibited effectively, whereas in the adenovirus treatment experiment, the effect of survivin shRNA in xenografts is restricted locally around the pathway of injection. Although we used a multiple-site injection for the delivery of Ad-shSur into the tumor mass, it is impossible to deliver shRNA into all the cancer cells. Hence, we consider that adenovirusmediated shRNA strategy should be combined with other curative approaches for the treatment of HCC.
In conclusion, we established reporter-siRNA screening-based AdshRNA system specifically to suppress survivin overexpression in HCC. Our result showed that survivin shRNA alone was sufficient to induce profound dysregulation of mitosis and spontaneous apoptosis and even to sensitize HCC cells to proapoptotic agents. We have shown the important role of the strategy of interference of survivin expression in the suppression of initiation and progression of HCC, and indicated that adenovirus-mediated survivin siRNA may provide a new avenue for further development of therapeutic strategies for the treatment of HCC.
